Premium
Phase‐based arterial input function measurements in the femoral arteries for quantification of dynamic contrast‐enhanced (DCE) MRI and comparison with DCE‐CT
Author(s) -
Korporaal Johannes G.,
van den Berg Cornelis A. T.,
van Osch Matthias J. P.,
Groenendaal Greetje,
van Vulpen Marco,
van der Heide Uulke A.
Publication year - 2011
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.22905
Subject(s) - dynamic contrast , medicine , nuclear medicine , dynamic contrast enhanced mri , phase (matter) , prostate cancer , contrast (vision) , magnetic resonance imaging , prostate , radiology , cancer , chemistry , physics , optics , organic chemistry
Dynamic contrast‐enhanced (DCE) MRI is useful for diagnosis, treatment monitoring and follow‐up of prostate cancer. However, large differences have been reported in the parameter range of the transfer constant K trans , making longitudinal studies and comparison of DCE‐MRI findings between studies difficult. Large part of this inconsistency in K trans values can be attributed to problems with the accurate measurement of the arterial input function (AIF) from the magnitude signal (AIF MAG N ). Phase‐based AIF measurements (AIF PHASE ) have been proposed as a more robust alternative to AIF MAG N measurements. This study compares AIF PHASE with AIFs measured with DCE‐CT (AIF CT ), and the corresponding K trans maps in 12 prostate cancer patients. The shape of AIF PHASE and AIF CT are similar, although differences in the peak height and peak width exist as a result of differences in injection protocol. No significant differences in K trans values were found between the DCE‐MRI and DCE‐CT exams, with median K trans values of 0.10 and 0.08 min −1 for healthy peripheral zone tissue and 0.44 and 0.36 min −1 for regions suspected of tumor respectively. Therefore, robust quantification of K trans values from DCE‐MRI exams in the cancerous prostate is feasible with the use of AIF PHASE . Magn Reson Med, 2011. © 2011 Wiley Periodicals, Inc.